Business Context and Reporting Period
This Form 8-K filing by Hemispherx Biopharma, Inc. (HEB) reports on events occurring on May 29, 2019, regarding a Special Meeting of Stockholders. The company is incorporated in Delaware and trades on the NYSE American. Note: The request metadata references "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and capital structure adjustments rather than operational financial performance.
Material Changes
The primary material change reported is the stockholder approval of a reverse stock split. At the Special Meeting held on May 29, 2019, stockholders voted to authorize the Board to amend the Certificate of Incorporation to effect a reverse split with a ratio between 1-for-20 and 1-for-50. The Board subsequently determined the specific ratio to be 1-for-44.
- Voting Results: 37,584,479 votes For; 5,396,070 votes Against; 634,293 Abstain.
- Approval Rate: Approximately 55% of all issued and outstanding shares; approximately 86% of shares actually voted.
- Effective Date: June 10, 2019.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the execution of the reverse stock split. The Board exercised its discretion to set the split ratio at 1-for-44 following the meeting. Further details are referenced in a press release dated May 31, 2019 (Exhibit 99.1).
Investor Verification Checklist
- Verify the effective date of the 1-for-44 reverse stock split (June 10, 2019) and its impact on share count and price.
- Confirm the company's current ticker symbol and exchange listing status post-split.
- Review the attached press release (Exhibit 99.1) for additional context on the rationale for the split.
- Check subsequent filings for updated financial statements reflecting the capital structure change.